Top Suppliers:I want be here

  • BioBioPha
  • China
  • Product Name: Corosolic acid
  • Price: ¥Inquiry/5mg
  • Purity: 97.0%
  • Stocking Period: 10 Day
  • Contact: Xueping-Zheng



4547-24-4

4547-24-4 structure
4547-24-4 structure
  • Name: Corosolic acid
  • Chemical Name: Corosolic acid
  • CAS Number: 4547-24-4
  • Molecular Formula: C30H48O4
  • Molecular Weight: 472.700
  • Catalog: Biochemical Natural product
  • Create Date: 2018-08-01 21:14:36
  • Modify Date: 2024-01-02 18:07:47
  • Corosolic acid isolated from the fruit of Cratoegus pinnatifida var. psilosa, was reported to have anticancer activity.IC50 value: 26.8 μg/ml in vitroTarget:In vitro: Corosolic acid displayed about the same potent cytotoxic activity as ursolic acid against several human cancer cell lines. In addition, the compound displayed antagonistic activity against the phorbol ester-induced morphological modification of K-562 leukemic cells, indicating the suppression of protein kinase C (PKC) activity by the cytotoxic compound. The compound showed PKC inhibition with dose-dependent pattern in an in vitro PKC assay [1]. MTT method was used to detect the influence of corosolic acid on A549 lung cancer cell growth in vitro under different concentrations. The value of IC50 was 26.8 μg/ml in vitro experiment. Corosolic acid of different doses had certain therapeutic effects on A549 solid tumor, the content of VEGF and CD34 proteins also had different degrees of influence [2]. Corosolic acid induced apoptosis in CT-26 cells, mediated by the activation of caspase-3. It inhibited the proliferation and tube formation of human umbilical vein endothelial cells and human dermal lymphatic microvascular endothelial cells, decreased the proliferation and migration of human umbilical vein endothelial cells stimulated by angiopoietin-1 [3]. In vivo: A mouse colon carcinoma CT-26 animal model was employed to determine the in vivo anti-angiogenic and anti-lymphangiogenic effects of corosolic acid.

Name Corosolic acid
Synonyms 2-a-hydroxyursolic acid
hydroxyursolic acid
Corosolic acid
Urs-12-en-28-oic acid, 2,3-dihydroxy-, (2α,3β)-
2,3-dihydroxyurs-12-en-28-oic acid
2alpha-hydroxyursolic acid
2α-Hydroxyursolic acid
MFCD03840521
(2α,3β)-2,3-Dihydroxyurs-12-en-28-oic acid
Description Corosolic acid isolated from the fruit of Cratoegus pinnatifida var. psilosa, was reported to have anticancer activity.IC50 value: 26.8 μg/ml in vitroTarget:In vitro: Corosolic acid displayed about the same potent cytotoxic activity as ursolic acid against several human cancer cell lines. In addition, the compound displayed antagonistic activity against the phorbol ester-induced morphological modification of K-562 leukemic cells, indicating the suppression of protein kinase C (PKC) activity by the cytotoxic compound. The compound showed PKC inhibition with dose-dependent pattern in an in vitro PKC assay [1]. MTT method was used to detect the influence of corosolic acid on A549 lung cancer cell growth in vitro under different concentrations. The value of IC50 was 26.8 μg/ml in vitro experiment. Corosolic acid of different doses had certain therapeutic effects on A549 solid tumor, the content of VEGF and CD34 proteins also had different degrees of influence [2]. Corosolic acid induced apoptosis in CT-26 cells, mediated by the activation of caspase-3. It inhibited the proliferation and tube formation of human umbilical vein endothelial cells and human dermal lymphatic microvascular endothelial cells, decreased the proliferation and migration of human umbilical vein endothelial cells stimulated by angiopoietin-1 [3]. In vivo: A mouse colon carcinoma CT-26 animal model was employed to determine the in vivo anti-angiogenic and anti-lymphangiogenic effects of corosolic acid.
Related Catalog
References

[1]. Ahn KS, et al. Corosolic acid isolated from the fruit of Crataegus pinnatifida var. psilosa is a protein kinase C inhibitor as well as a cytotoxic agent. Planta Med. 1998 Jun;64(5):468-70.

[2]. LI Biao, et al. Mechanism of antitumor action of corosolic acid. China Journal of Modern Medicine, 2015-08

[3]. Ki Hyun Yoo, et al. Corosolic Acid Exhibits Anti-angiogenic and Anti-lymphangiogenic Effects on In Vitro Endothelial Cells and on an In Vivo CT-26 Colon Carcinoma Animal Model. Phytotherapy Research, 2015, 29 (5): 14–723

Density 1.1±0.1 g/cm3
Boiling Point 573.3±50.0 °C at 760 mmHg
Molecular Formula C30H48O4
Molecular Weight 472.700
Flash Point 314.6±26.6 °C
Exact Mass 472.355255
PSA 77.76000
LogP 7.82
Vapour Pressure 0.0±3.6 mmHg at 25°C
Index of Refraction 1.567
Storage condition 2-8°C

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name: Corosolic acid
REACH No.: A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No.: 4547-24-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses: Laboratory chemicals, Manufacture of substances



SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

SECTION 3: Composition/information on ingredients
Substances
Formula: C30H48O4
Molecular Weight: 472,70 g/mol
CAS-No.: 4547-24-4
No components need to be disclosed according to the applicable regulations.

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) AppearanceForm: powder
Colour: white
b) Odourno data available
c) Odour Thresholdno data available
d) pHno data available
e) Melting point/freezingMelting point/range: 243 - 245 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash pointno data available
h) Evapouration rateno data available
i) Flammability (solid, gas) no data available
j) Upper/lowerno data available
flammability or
explosive limits
k) Vapour pressureno data available
l) Vapour densityno data available
m) Relative densityno data available
n) Water solubilityno data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignitionno data available
temperature
q) Decompositionno data available
temperature
r) Viscosityno data available
s) Explosive propertiesno data available
t) Oxidizing propertiesno data available
Other safety information
no data available

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC:No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
change in serum glucose level

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: -IMDG: -IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA:Not dangerous goods
Transport hazard class(es)
ADR/RID: -IMDG: -IATA: -
Packaging group
ADR/RID: -IMDG: -IATA: -
Environmental hazards
ADR/RID: noIMDG Marine pollutant: noIATA: no
Special precautions for user
no data available



SECTION 15 - REGULATORY INFORMATION
N/A


SECTION 16 - ADDITIONAL INFORMATION
N/A
RIDADR NONH for all modes of transport

~98%

4547-24-4 structure

4547-24-4

Literature: Wen, Xiaoan; Sun, Hongbin; Liu, Jun; Cheng, Keguang; Zhang, Pu; Zhang, Liying; Hao, Jia; Zhang, Luyong; Ni, Peizhou; Zographos, Spyros E.; Leonidas, Demettes D.; Alexacou, Kyra-Melinda; Gimisis, Thanasis; Hayes, Joseph M.; Oikonomakos, Nikos G. Journal of Medicinal Chemistry, 2008 , vol. 51, # 12 p. 3540 - 3554

~%

4547-24-4 structure

4547-24-4

Literature: Use- Techno Corporation Patent: US2005/137259 A1, 2005 ; Location in patent: Page/Page column 5 ;

~%

4547-24-4 structure

4547-24-4

Literature: Wen, Xiaoan; Sun, Hongbin; Liu, Jun; Wu, Guanzhong; Zhang, Luyong; Wu, Xiaoming; Ni, Peizhou Bioorganic and Medicinal Chemistry Letters, 2005 , vol. 15, # 22 p. 4944 - 4948

~%

4547-24-4 structure

4547-24-4

Literature: Wen, Xiaoan; Sun, Hongbin; Liu, Jun; Wu, Guanzhong; Zhang, Luyong; Wu, Xiaoming; Ni, Peizhou Bioorganic and Medicinal Chemistry Letters, 2005 , vol. 15, # 22 p. 4944 - 4948

~%

4547-24-4 structure

4547-24-4

Literature: Wen, Xiaoan; Sun, Hongbin; Liu, Jun; Wu, Guanzhong; Zhang, Luyong; Wu, Xiaoming; Ni, Peizhou Bioorganic and Medicinal Chemistry Letters, 2005 , vol. 15, # 22 p. 4944 - 4948

~%

4547-24-4 structure

4547-24-4

Literature: Wen, Xiaoan; Sun, Hongbin; Liu, Jun; Wu, Guanzhong; Zhang, Luyong; Wu, Xiaoming; Ni, Peizhou Bioorganic and Medicinal Chemistry Letters, 2005 , vol. 15, # 22 p. 4944 - 4948

~%

4547-24-4 structure

4547-24-4

Literature: Das, Manik C.; Mahato, Shashi B. Phytochemistry (Elsevier), 1982 , vol. 21, # 8 p. 2069 - 2074

~%

4547-24-4 structure

4547-24-4

Literature: Talapatra, Bani; Chaudhuri, Prabir K.; Mallik, Asok K.; Talapatra, Sunil K. Phytochemistry (Elsevier), 1983 , vol. 22, # 11 p. 2559 - 2562

~%

4547-24-4 structure

4547-24-4

Literature: Glen,A.T. et al. Journal of the Chemical Society [Section] C: Organic, 1967 , vol. , p. 510 - 515